New drug tested in patients with fatty liver and cirrhosis
NCT ID NCT07358546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrhosis and be between 18 and 70 years old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGRialto, California, 92377, United States
-
GSK Investigational Site
RECRUITINGTampa, Florida, 33603, United States
-
GSK Investigational Site
RECRUITINGSan Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune cells in fat hold the key to Obesity-Related disease?
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can fatty liver in children lead to serious liver disease? a Long-Term study aims to find out
- Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
- Can fish oil shrink a fatty liver?